Target Price | $6.63 |
Price | $2.43 |
Potential |
172.63%
register free of charge
|
Number of Estimates | 12 |
12 Analysts have issued a price target Fate Therapeutics, Inc. 2025 .
The average Fate Therapeutics, Inc. target price is $6.63.
This is
172.63%
register free of charge
$12.00
393.83%
register free of charge
$3.50
44.03%
register free of charge
|
|
A rating was issued by 17 analysts: 4 Analysts recommend Fate Therapeutics, Inc. to buy, 12 to hold and 1 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Fate Therapeutics, Inc. stock has an average upside potential 2025 of
172.63%
register free of charge
|
Dec '23 |
2024 Estimates |
|
---|---|---|
Revenue Million $ | 63.53 | 11.17 |
34.03% | 82.42% | |
EBITDA Margin | -250.79% | -1,678.69% |
18.03% | 569.35% | |
Net Margin | -293.90% | -1,672.83% |
14.57% | 469.19% |
17 Analysts have issued a sales forecast Fate Therapeutics, Inc. 2024 . The average Fate Therapeutics, Inc. sales estimate is
This results in the following potential growth metrics:
5 Analysts have issued an Fate Therapeutics, Inc. EBITDA forecast 2024. The average Fate Therapeutics, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
18 Fate Therapeutics, Inc. Analysts have issued a net profit forecast 2024. The average Fate Therapeutics, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '23 |
2024 Estimates |
|
---|---|---|
Earnings Per Share $ | -1.64 | -1.64 |
43.64% | 0.00% | |
P/E | negative | |
EV/Sales | 6.48 |
18 Analysts have issued a Fate Therapeutics, Inc. forecast for earnings per share. The average Fate Therapeutics, Inc. <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2024, the Fate Therapeutics, Inc. stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
Fate Therapeutics, Inc....
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.